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The signalling pathways underpinning cell growth and invasion use overlapping components,
yet how mutually exclusive cellular responses occur is unclear. Here, we report development
of 3-Dimensional culture analyses to separately quantify growth and invasion. We identify
that alternate variants of IQSEC1, an ARF GTPase Exchange Factor, act as switches to pro-
mote invasion over growth by controlling phosphoinositide metabolism. All IQSEC1 variants
activate ARF5- and ARF6-dependent PIP5-kinase to promote PI(3,4,5)P3-AKT signalling and
growth. In contrast, select pro-invasive IQSEC1 variants promote PI(3,4,5)P3 production to
form invasion-driving protrusions. Inhibition of IQSEC1 attenuates invasion in vitro and
metastasis in vivo. Induction of pro-invasive IQSEC1 variants and elevated IQSEC1 expression
occurs in a number of tumour types and is associated with higher-grade metastatic cancer,
activation of PI(3,4,5)P3 signalling, and predicts long-term poor outcome across multiple
cancers. IQSEC1-regulated phosphoinositide metabolism therefore is a switch to induce
invasion over growth in response to the same external signal. Targeting IQSEC1 as the central
regulator of this switch may represent a therapeutic vulnerability to stop metastasis.
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A central conundrum in biology is that highly overlappingsignalling pathways regulate distinct biological outputs.For instance, activation of receptor tyrosine kinases
(RTKs), and their downstream effectors such as the MAPK-ERK
and PI3K-Akt pathway, can induce either growth or invasion.
Since the development of invasive features and the progressive
loss of normal tissue organisation are hallmarks of tumour pro-
gression1 understanding how cells decode their response to
external signals has significant clinical implications.
Metastasis is the major cause of cancer-related death, increas-
ingly recognised as a collective migration event. For a collection of
epithelial cells to invade they must undergo rearrangement of
normal apical–basal cellular polarisation to clusters or chains of
cells lead by an invasive front. The use of 3-dimensional (3D)
culture systems, whereby epithelial cells are embedded in gels of
extracellular matrix (ECM) to undergo collective morphogenesis,
has illuminated the molecular mechanisms of collective cell
polarisation2–6. Such polarity rearrangements can be achieved via
altered membrane trafficking of morphogenesis-regulating pro-
teins. For collective invasion to occur, signalling receptors, such as
RTKs, must be directed to domains where a pro-invasive ligand is
exposed. Some RTKs, such as the HGF receptor Met, require
internalisation and endosomal localisation for full oncogenic
signalling7–9. Additional membrane trafficking steps, such as
recycling back to the cortex, can provide sustained signalling to
effectors10. However, what controls whether such signals result in
tumour cell growth versus the induction of collective invasion and
metastasis remains unclear.
The ARF family of small GTPases (ARF1–6) are implicated in
the membrane trafficking and signalling mechanism underpinning
single cell invasion11–16. ARF GTPases have fundamental roles in
vesicular transport by regulating assembly of coat complexes, lipid-
modifying enzymes, and recruiting regulators of other GTPases
onto membranes undergoing scission17. ARF6 in particular controls
internalisation and recycling of RTKs by acting in concert with a
number of GTP exchange factors (GEFs)18–21 and GTPase-
activating proteins (GAPs)22–26. Accordingly, small molecule ARF
GEF or GAP inhibitors have been used to control invasion in vitro
and metastasis in vivo23,27–29.
Despite the core requirement for ARF GTPases in membrane
trafficking steps controlling RTK signalling, it remains unclear
how they could promote an invasion response, rather than
growth, from an RTK. Are particular ARF-regulated trafficking
pathways induced in invasive cells, such as to enhance endocytic
recycling and sustained RTK activation, to promote invasion over
growth? Here, we describe that specific pro-invasive transcript
variants of the ARF GEF IQSEC1 are upregulated in invasive
tumours. These alternate variant proteins act as scaffolds to direct
phosphoinositide metabolism to induce invasive protrusions. We
identify that IQSEC1 can be targeted to inhibit collective invasion
in vitro and metastasis in vivo.
Results
Expression of the ARF GEF IQSEC1 is associated with poor
clinical outcome. We examined whether ARF GTPase expression
was associated with the acquisition of invasive behaviours. We
used 3D culture of prostate cancer cell lines to represent the
transition from non-tumorigenic to highly metastatic (Fig. 1a).
Non-tumorigenic RWPE-1 cells30 formed acini with a central
lumen (Fig. 1a, b). RWPE-2, an oncogenic KRAS-expressing
RWPE-1 variant30 formed lumen-lacking aggregates, some of
which developed invasive cell chains (Fig. 1b, white arrowheads).
Bone metastasis-derived PC3 cells31 grew as heterogeneous acini,
variably forming round, locally spread, or spindle-shaped invasive
cell chains (Fig. 1c). Multiday live imaging revealed that invasive
chains were derived from single cells that first formed spherical
aggregates (growth phase) that initially protruded into matrix,
then elongated into chains (Fig. 1c, arrowheads, invasion phase).
ARF GTPases function with GEFs and GAPs that control their
nucleotide-association state (Fig. 1d)17. We observed an associa-
tion of the GEF IQSEC1 (also called BRAG2/GEP10032) with
prostate tumorigenesis. All ARF GTPases, and a number of ARF
GEFs were upregulated in PC3 cells (Fig. 1e, g). IQSEC1,
including multiple isoforms, was a strongly expressed GEF in
RWPE-2 and PC3. Normal prostate and breast cells expressed
low levels of IQSEC1, while invasive lines (PC3, VCaP) had
upregulated IQSEC1 mRNA, with little variation in copy number
(Fig. 1g). Western blotting of androgen receptor (AR)-proficient
and -deficient prostate lines confirmed upregulation of ARF6 and
IQSEC1 protein expression in metastatic prostate cancer cell lines
(LNCaP, VCaP, DU145, PC3) (Fig. 1h). We focused on dissecting
IQSEC1 molecular function.
IQSEC1 is a regulator of collective cell invasion. We examined
the contribution of IQSEC1 to cell growth and movement. Pub-
licly available IQSEC1 transcript information revealed multiple
variants occurring through combinatorial use of alternate trans-
lational initiation sites and alternate splicing (Fig. 2a; Supple-
mentary Table 1). Western blotting suggested simultaneous
expression of multiple variants in PC3 cells, with three IQSEC1
bands depleted by IQSEC1-specific shRNAs (Supplementary
Fig. 1a). IQSEC1 depletion reduced proliferation proportional to
knockdown efficiency (Supplementary Fig. 1a, b). As PC3 cells
grow as a mixed morphology 3D culture (Fig. 1c), we developed a
machine learning approach to determine whether this hetero-
geneity also occurred in 2D (Supplementary Fig. 1c). Mirroring
3D collective phenotypes (Fig. 1c), single PC3 cells in 2D culture
could be classified into round (54%), spread (21%) and spindle
phenotypes (17%) (Supplementary Fig. 1d, e). IQSEC1 depletion
selectively abolished spindle characteristics, causing increased
spread behaviours (Supplementary Fig. 1f).
We examined whether IQSEC1-dependent spindle shape was
required for cell movement. Live imaging of wounded 2D
monolayers revealed cells of various shapes rapidly move into the
wound (Supplementary Fig. 1g). IQSEC1-depleted cells displayed
a modest defect in migration. In contrast, in 3D invasion assays
wounded monolayers embedded in ECM (Matrigel) invade by
forming spindle-shaped protrusions that develop into multi-
cellular chains (Supplementary Fig. 1h, white arrowheads). In
IQSEC1-depleted cells, although some protrusions formed,
multicellular chain formation and invasive activity was strongly
compromised (Supplementary Fig. 1h, i). Thus, IQSEC1 is
required for growth and multicellular invasive chain formation,
resulting in defects in morphogenesis where cell elongation is
required (Supplementary Fig. 1j).
IQSEC1 is a regulator of collective 3D invasion. We dissected
IQSEC1 contribution to growth and/or invasion in 3D PC3 acini,
which can form without (round) or with (spindle) invasive
characteristics (Fig. 1c). In order to quantify this growth versus
invasive behaviour we developed an automated method of
quantitation from hourly imaging of hundreds to thousands of
3D acini over multiple days (see the “Methods” section and
Supplementary Fig. 2a).
Elevated IQSEC1 expression in PC3 cells, compared to
RWPE-1 cells, was maintained upon plating of both cell types
into 3D culture (Fig. 2b). Growth of acini from single cells could
be measured by increased area over time (Supplementary
Fig. 2b, c). The progressive development of protrusive invasion
could be determined using a ‘Compactness’ measurement
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(Supplementary Fig. 2b, c; Supplementary Movies 1 and 2).
Similar to 2D, IQSEC1 depletion modestly decreased 3D acinar
growth (Supplementary Fig. 2c), proportional to depletion levels
(Supplementary Fig. 1a). Mirroring 3D wound invasion defects
(Supplementary Fig. 1h), the most prominent effect of IQSEC1
depletion was abolished protrusive invasion (Supplementary
Fig. 2b, c).
We examined whether protrusion-forming activity was a
common feature of all IQSEC1 isoforms. We focused on the
four annotated variants (v1–4; Fig. 2a). IQSEC1 v1–4 possess the
IQSEC family-defining features of a calmodulin-binding IQ
domain, a catalytic SEC7 ARF GEF domain, and a lipid-binding
PH domain. Alternate initiation sites provide v1 or v2 with
unique N-termini, followed by a common N-terminal extension.
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Three alternate C-termini can occur, with the v4-type tail
truncating a potential nuclear localisation sequence.
We stably, individually restored each RNAi-resistant GFP-
tagged IQSEC1 variant in the background of depletion of all
endogenous IQSEC1 transcripts. All IQSEC1 variants could
restore growth and/or invasion to levels matching or above
control cells (Fig. 2c–f). Variants containing the N-terminal
extension (v1, v2) conferred the strongest effect on growth. In
contrast, protrusive activity occurred in an isoform-selective
manner: only v2 (also known as BRAG2b) restored spindle
behaviours in both 2D and 3D to levels surpassing controls
(Fig. 2e, f; S2D). To corroborate the live imaging approach we
examined fixed acini through 3D confocal imaging. Restoration of
v2 to IQSEC1 KD cells increased the total number of nuclei, the
level of a proliferation marker (Ki67) and suppressed apoptosis
without changing total acinus volume (Supplementary Fig. 2e–h).
This represented formation of protrusions and disruption to
lumen formation. In contrast, v4 failed to rescue IQSEC1 KD-
induced growth defects, but instead increased area by increasing
acinus volume without changing cell number, due to the presence
of a lumen. Thus, IQSEC1 v2 is a major regulator of 3D growth
and invasion.
We explored the IQSEC1 v2 properties that promote invasion.
IQSEC1 can function in ARF GTPase-dependent endocytosis at
the cell cortex, and in the nucleus to control nucleolar
architecture32,33. V3 showed predominantly nuclear localisation,
while v4 was cortical (Figs. 2g, S2i). V1 showed mixed cortical
and cytoplasmic localisation. In contrast, v2 displayed a mix of
cytoplasmic, cortical and nuclear labelling (Fig. 2g, green
arrowheads, S2i). We reasoned that in overexpressed GFP-
tagged variants may mask vesicular pools. Accordingly, anti-
IQSEC1 antibodies directed to either all isoforms or to v2-
specifically (Fig. 2h) labelled both the cytoplasm and tubulove-
sicular compartments behind the tips of invasive acinar
protrusions in 3D (Fig. 2i–k, arrowheads, S2j, k). Thus, one
locale of IQSEC1 v2 function is focally at endosomes in
protrusion tips (Fig. 2i–k).
We mapped the domains of v2 responsible for its localisation
and potent invasion-inducing activity. We expected that this
would be conferred by the unique v2 N-terminus. However, using
mutants and chimeras of IQSEC1 isoforms revealed a nuanced
and combinatorial effect of alternate N- and C-termini on
IQSEC1 localisation and protrusion induction (Supplementary
Fig. 3a–g). Surprisingly, the unique v2 N-terminus (2N) was not
required for invasion. Any variant containing the v2-tail and any
N-terminal extension promoted invasion. Accordingly, replacing
the unique v2 N-terminus (2N) with that from v1 (1N) even
enhanced invasion over and above that of v2 (Supplementary
Fig. 3e–g). This was concomitant with a shift away from nuclear
or cortical localisation, towards the cytoplasm (Supplementary
Fig. 3c, 1N/2C chimera). This is in contrast to expression of v1
which did not induce invasion (Fig. 2f). This is due to the
presence of a v1-type C-terminus (1C) which in all experiments
inhibits invasion, concomitant with a more general cortical
recruitment. A v2 tail without N-terminal extension (i.e. v3)
similarly does not promote invasion. This maps the invasion-
inducing activity of IQSEC1 to the N-terminal extension that is
common to only v1 and v2. However, the type of C-terminus
influences whether this N-terminus induces invasion (Supple-
mentary Fig. 3a–g). Mutational inactivation of GEF activity
(IQSEC1 v2GEF*) confirmed that IQSEC1 v2-induced spindle
shape in 2D (Supplementary Fig. 3b) and protrusive invasion in
3D (Supplementary Fig. 3d–g) are due to its ability to activate
ARF GTPases. Thus, the N-terminal common extension in v2
confers enhanced invasive activity in a GEF-dependent manner.
IQSEC1 activates ARF5/6 in distinct locations within protru-
sions. IQSEC1 functions with both ARF5 and ARF6 to control
integrin endocytosis and focal adhesion disassembly13,34. Given
IQSEC1 GEF activity-dependency for invasion (Supplementary
Fig. 3d–g), we examined whether ARF5 and ARF6 are required
for this process. While individual ARF depletion caused some
changes that mimicked IQSEC1 loss, only combined ARF5/6
depletion reduced all aspects of 2D spindle shape and 3D growth
and invasion (Fig. 3a–c, S4a). We examined whether individual or
co-overexpression (OX) of ARF5 or ARF6, wild-type (WT) or
fast-cycling mutants (Supplementary Fig. 4b, c)13,35 induced
invasive behaviours. Only ARF5/6 WT co-overexpression
increased 2D spindle shape, 3D growth and 3D invasion
(Fig. 3d–f, S4d–g). While fast-cycling mutants induced some 2D
spindle behaviours, they failed to induce 3D effects, either alone
or in combination, indicating that normal GTPase cycling was
required. Crucially, IQSEC1 depletion abolished all effects of
ARF5/6 co-overexpression (Fig. 3d–f, S4h). This identifies
IQSEC1 as the major GEF-regulating growth and invasion with
ARF5/6 as its major targets.
Despite identifying IQSEC1 GEF activity as essential for
growth and invasion (Supplementary Fig. 3e–g) we did not
observe global defects in GTP-loading of ARF5 or ARF6 upon
IQSEC1 depletion (Supplementary Fig. 4i). As IQSEC1 v2
localised to a discrete pool at tips of protrusions (Fig. 2j), we
reasoned that IQSEC1 may regulate a small but crucial ARF5/6
pool. We developed an imaging-based approach to determine the
localisation of the IQSEC1–ARF complex. Endogenous IQSEC1
v2 localised with ARF5-mNeonGreen and ARF6-TagRFPT in
tubulovesicular structures near the leading edge lamellipodium of
spindle 2D cells (Fig. 3g, white arrowheads). In 3D, ARF5
displayed a prominent vesicular localisation in the acinus body,
which overlapped with IQSEC1 in some regions, while ARF6 was
prominent at cell–cell contacts lacking IQSEC1 (Fig. 3h, yellow
arrowheads and white arrows, respectively). Both ARF5 and
ARF6 could be found with IQSEC1 v2 in protrusion tips (Fig. 3h,
white arrowheads).
Fig. 1 Upregulation of IQSEC1 is associated with tumorigenesis. a Schema, prostate cell lines forming non-invasive or invasive 3D acini in extracellular
matrix (ECM). b Cartoon, phenotype of typical RWPE-1 and RWPE-2 acini. Confocal (F-actin (red) and nuclei (blue)) and brightfield images show RWPE-1
and RWPE-2 acini (120 h). Arrowheads, protrusions. n= 3 independent experiments with 3 replicates/condition. Scale bar, 20 μm. c Schema, PC3 acini
form (grow) and invade (protrusions) through ECM over time. Phase contrast images of PC3 acini where higher magnification of boxed region at different
time points is shown. Arrowheads, protrusions. n= 3 independent experiments with 3 replicates/condition. Scale bar, 100 μm. d Cartoon, ARF GTPase
cycle. e Heatmap representation of mRNA expression from q-PCR. Data are normalised to RWPE-1 and presented as the log2-transformed fold change
compared to the average of all values. Bar graphs summarise fold changes of ARF and IQSEC mRNA levels. Mean ± s.d., n= 3 biological replicates. p-values;
Student’s t-test (2-tailed). *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 and ****p≤ 0.0001. f Schema, elevated activation of ARF GTPases in PC3 cells by GEFs such
as IQSEC1. g Graph generated using RNAseq data from the Cancer Cell Line Encyclopaedia (CCLE) comparing IQSEC1 gene copy number and mRNA
expression levels in multiple breast and prostate cancer and non-transformed cell lines. h Western blot analysis of androgen receptor (AR) proficient or
deficient prostate cell lines using anti-ARF1, ARF6, pan-IQSEC1 isoform and GAPDH (as sample control) antibodies. n= 2 independent experiments.
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To identify the location of active ARF we expressed a sensor
that detects GTP-loaded ARF proteins (GGA1 NGAT domain36)
(Fig. 3i). GGA1 NGAT-TagRFP-T colocalized with ARF6 most
notably in the tips of protrusions (Fig. 3j, green arrowheads), and
with ARF5 in puncta in the body of the protrusion (white
arrowheads) and the acinus body itself (white arrows).
To confirm that IQSEC1 was controlling this localised GTP
loading of ARF5/6 we developed an automated method to analyse
the percentage of overlap of the GGA1-NGAT probe with ARF5-
or ARF6-positive puncta. We validated the sensitivity of this
approach by first examining whether chemical inactivation of
ARF GEF or GAP activity could be detected (Fig. 3i). We
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identified that a reported ARF6 inhibitor (NAV-2729)29, but not
the Cytohesin family ARF GEF inhibitor (Secin-H3)37,38, also
reduces IQSEC1-catalysed nucleotide exchange on ARF5 (Sup-
plementary Fig. 4j, k). In cells, NAV-2729 significantly decreased
GGA1-NGAT recruitment to both ARF5 and ARF6-positive
puncta (Fig. 3k, l). In contrast, the ARF GAP inhibitor
QS11 significantly increased GGA1-NGAT recruitment to
ARF6, while decreasing recruitment to ARF5. Thus, our approach
sensitively detects GTP-loading of specific ARF subpopulations
(Fig. 3j-l). Applying this approach in IQSEC1-depleted cells we
observed a robust decrease, but not complete loss, of recruitment
of GGA1-NGAT to both ARF5 and ARF6 (Fig. 3j–l). These data
confirmed that IQSEC1 controls GTP loading of a pool of ARF5/
6 that is crucial for invasive activity (Fig. 3m).
We determined the morphogenetic effect of modulating ARF
activity. Secin-H3 treatment, which minimally acts on IQSEC1-
mediated ARF activation (Supplementary Fig. 4k) modestly
decreased 3D growth, without affecting invasion (Supplementary
Fig. 4l–o). ARFGAP inhibition (QS11)27,38 increased 3D inva-
sion, without affecting growth. However, in line with being a dual
IQSEC1-ARF5/6 inhibitor, NAV-2729 treatment abolished 3D
growth and invasion. Thus, ARF5 and ARF6 are the major targets
of IQSEC1 GEF activity. Chemical or genetic inhibition of
IQSEC1-directed ARF activation strongly attenuates 3D growth
and invasion.
IQSEC1 is a scaffold for Met and Akt signalling. All IQSEC1
variants possess the SEC7-PH domains required to activate ARF
GTP loading (Fig. 4a). The enhanced invasion-promoting cap-
abilities of IQSEC1 v2 are conferred by the shared N-terminal
extension (encoded by Exon 3; Fig. 4a). We used mass spectro-
metry protein–protein interaction analysis of IQSEC1 chimeras to
identify domain-specific IQSEC1 binding partners. We classified
interactors as unique to v1 or v2 N-termini (1N or 2N), shared
between v1 or v2 N-terminal extension (Exon 3), to the core IQ-
SEC7-PH region (Core), or specific to the v2 C-terminus (2C)
(Fig. 4a). We prioritised interactors where multiple components
of a complex could be identified. We ordered these by mRNA
expression change from two pairs of PC3-derived sublines which
possess epithelioid (PC3E, Epi) compared to mesenchymal
properties (GS689.Li, EMT14)39,40, to focus on invasion reg-
ulators (Fig. 4a–c). Using this approach, we identified the inter-
action of IQSEC1 with a number of oncogenic signalling
pathways (mTORC2, RAF, NFkB), cytoskeletal and scaffolding
complexes (Utrophin, 14-3-3), a phosphatase (PP6), and traf-
ficking complexes (EARP, AP3/ARFGAP1). In addition to the
known interactors Calmodulin-1/-2, we also identified three
transmembrane receptors (Met, LRP1 and SORL1), and other
factors (TUBB6, FHOD1). We confirmed a number of these
IQSEC1 interactors in independent immunoprecipitations, and
interactor protein level alterations by western blotting of a series
of PC3-derived sublines with varying invasive abilities (Fig. 4d,
S5a–c).
We initially focused on transmembrane interactors of IQSEC1.
IQSEC1 associated with Met, the receptor for HGF. This occurred
through the core region, indicating that all IQSEC1 variants can
potentially interact with Met (Fig. 4d, e, S5a). In contrast, two
proteins interacted only with the invasion-inducing regions of
IQSEC1: Low density lipoprotein receptor-Related Protein 1
(LRP1) and Sortilin-Related Receptor 1 (SORL1), members of the
LDL Receptor family (Fig. 4d, e, S5a). LRP1 and SORL1 protein,
however, displayed a mutually exclusive expression: LRP1
expression was elevated in invasive PC3 sublines (EMT14,
GS689.Li), whereas SORL1 was associated with epithelial sublines
(PC3E, Epi) and was anti-correlated with active pY1234/1235-
Met (pMet) levels in cells (Supplementary Fig. 5b, c). In addition,
LRP1 and Met both localised to the tips of invasive protrusions in
3D (Fig. 4f, g), and formed a complex irrespective of IQSEC1
expression levels (Supplementary Fig. 5d). These data suggest that
LRP1 and Met form a complex in the tips of protrusions onto
which IQSEC1 associates to promote invasion.
Supporting the enrichment of active Met and LRP1 in invasive
PC3 sublines (Supplementary Fig. 5a–c), depletion of LRP1 or
Met reduced spindle shape in 2D and attenuated 3D growth and
invasion (Fig. 4h, i, S5e–g). LRP1 is a 600 kDa protein that is
cleaved to release a 515 kDa extracellular fragment and an 85 kDa
transmembrane receptor41,42. Expression of a GFP-tagged
transmembrane LRP1 fragment (LRP1TM-GFP) was not sufficient
to induce invasion, suggesting both transmembrane and extra-
cellular LRP1 fragments are required for invasion (Supplementary
Fig. 5h). In contrast, SORL1 depletion increased spindle
behaviours in 2D but did not significantly affect invasion or
growth in 3D (Fig. 4h, i, S5g, i–k). These data support a positive
role for LRP1/Met in invasion, while SORL1 may be antagonistic.
We examined downstream signalling from Met that drives
invasion. We focused on signalling to the TORC2-Akt pathway,
as multiple subunits of this complex (RICTOR, SIN1/MAPKAP1,
PRKDC) associated with IQSEC1. RICTOR is an essential
positive regulator of mTORC243,44, while SIN1 has been reported
to inhibit mTORC2 activity45. Accordingly, RICTOR depletion
robustly abolished Akt S473 phosphorylation (pAkt), spindle
shape in 2D, and 3D invasion and growth (Fig. 4h, i, S5g, j–l).
Fig. 2 IQSEC1 isoforms differentially regulate collective invasion. a Schema, domain structure of IQSEC1 variants (v). Common domains, grey. Unique
domains, colour: blue, v1; pink, v2 and v3; green, v4. bWestern blot in 2D and 3D using anti-IQSEC1 or GAPDH antibodies. Relative expression of all IQSEC1
bands normalised to 2D RWPE1 is shown. Mean ± s.d., n= 6 independent experiments. p-values (Student’s 2-tailed t-test), *p≤ 0.05; n.s., not significant.
c Schema, pipeline for identifying isoform-specific IQSEC1 functions. d Western blot of PC3 cells expressing GFP or GFP-IQSEC1 v1–v4, and either Scr or
IQSEC1 KD4 shRNA using anti-IQSEC1, GFP and GAPDH antibodies (all used on same membrane). Different exposures demonstrate expression of all
variants. Upper and lower parts of same GFP blot demonstrate expression of GFP-IQSEC1 variants and GFP control. N= 3 independent experiments. e and
f Phase images of acini (GFP-positive, yellow) from cells described in (d). Scale bars, 100 μm. Heatmap, area and compactness measurements Z-score-
normalised to control values. p-values, one-way ANOVA, greyscale values as indicated. n= 3 independent experiments, 3 replicates/condition, 300–650
acini/condition in total. g PC3 acini described in (d) were stained for F-actin (black) and nuclei (magenta). Localisation of GFP-IQSEC1 can be appreciated
from FIRE pseudo-coloured Look Up Table (FIRE LUT) (green arrowheads, cytoplasmic localisation). Magnified images are inset. n= 3 independent
experiments. Scale bars, 20 μm. Cartoon, localisation of GFP-IQSEC1 variants in PC3 acini. h Western blot of PC3 cells expressing GFP or GFP-IQSEC1
v1–v4 using anti-IQSEC1 (v2-specific) or GAPDH (loading control) antibodies. Different exposures allow detection of all variants. Upper and lower parts of
same GFP blot are shown to demonstrate expression of GFP-IQSEC1 variants and GFP control. i Schema, summary of the effect of IQSEC1 KD and GFP-
IQSEC1 v2 expression on growth and protrusive ability of PC3 acini. j Endogenous IQSEC1 v2 (green) co-stained with F-actin (red). Magnified images are
shown. Arrowhead indicates localisation at protrusion tip. n= 3 independent experiments. Scale bars, 10 μm. k IQSEC1-positive protrusion tips were
quantified (% positive/acinus) using antibodies which detect all variants (49 acini) or are specific for v2 (55 acini). Violin plot shows data distribution,
n= 2 independent experiments. p-values, Student’s 2-tailed t-test. n.s. not significant.
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Notably, while SIN1 depletion decreased spindle behaviours in
2D, it robustly increased invasion in 3D, suggesting 3D-specific
differences in this pathway (Fig. 4h, i, S5g, m). Finally, we
examined ARFGAP1 as a potential antagonist of IQSEC1-ARF
function. Unexpectedly, ARFGAP1 depletion phenocopied
IQSEC1 depletion: decreasing pAkt levels, spindle shape in 2D,
modestly decreasing 3D growth, and profoundly inhibiting 3D
invasion (Supplementary Fig. 5g, n–p). This suggests ARFGAP1
as an effector of ARF5/6 in regulating invasion and signalling to
the mTORC2-Akt pathway (Supplementary Fig. 5q), similar to
observation of dual effector-terminator functions of other
ARFGAPs46–48. Thus, an IQSEC1-ARF5/6-ARFGAP1 complex
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may control LRP1-Met signalling to mTORC2 during formation
of invasive 3D protrusions.
An IQSEC1–LRP1 complex modestly regulates Met endocytic
trafficking. Oncogenic Met signalling requires internalisation9.
We investigated whether IQSEC1 controls HGF-Met signalling to
Akt by controlling Met endocytic trafficking. HGF stimulation
increased 3D growth and robustly induced invasion, which was
substantially blunted by IQSEC1 depletion (Supplementary
Fig. 6a–d). ARF5/6 co-overexpression resulted in a modest but
consistent increase in pAkt levels, which was nonetheless atte-
nuated to levels similar to parental cells by IQSEC1 depletion
(Figs. 3d, 5a, b, S6a, b). This suggests that IQSEC1-ARF5/6
control signalling to the Akt pathway.
Paradoxically, IQSEC1-depleted cells displayed decreased total
Met levels (Supplementary Fig. 6a, b), but an increased half-life of
Met (Supplementary Fig. 6e), suggesting altered trafficking routes.
We examined whether this was due to altered endocytosis and/or
recycling of Met (Fig. 5c). We developed an image-based analysis
of Met trafficking using a fluorescently conjugated anti-Met
antibody (Fig. 5c, d). This allowed dual quantitation of
internalisation levels and localisation to cellular sub-regions
(membrane, cytoplasm, juxtanuclear). We detected some impact
of IQSEC1 depletion on Met trafficking, though in all instances
the magnitude of effect was modest. In control cells Met was
efficiently labelled at the cell surface, appeared in peripheral
endosomes after 10 min internalisation, then clustered in the
juxtanuclear region by 30min (Fig. 5d–f). IQSEC1-depleted cells
showed a modest but significant delay in the internalisation and
transit of Met from the periphery to the juxtanuclear region
(Fig. 5d–f), representing a decrease in total Met internalisation
levels. We observed no significant difference in recycling of
internalised Met (Fig. 5e, 10 min), but defects in internalisation
were re-apparent in extended time points of recycling that
allowed for re-internalisation (30 min). Thus, IQSEC1 is required
for efficient internalisation, but not recycling, of Met (Fig. 5f).
We examined whether the positive (LRP1) and negative
(SORL1) interactors of IQSEC1-regulated invasion we identified
may also function by controlling activated Met trafficking. LRP1/
SORL1 are regulators of endocytic sorting of a number of
transmembrane proteins49,50. In control cells, puncta containing
activated Met (pY1234/5-Met, pMet) were distributed throughout
the cytoplasm. Treatment with HGF induced a reduction in
peripheral pMet puncta, concomitant with puncta clustering in
the juxtanuclear region (Fig. 5g, h), which was abolished by
IQSEC1 depletion (Fig. 5h–j). Consistent with a positive role for
LRP1 in invasion LRP1, but not SORL1, depletion also blocked
redistribution of pMet away from the cell periphery in response
to HGF (Fig. 5h–j). These data reveal that IQSEC1 and LRP1
control Met-induced invasion by regulating Met transport to the
juxtanuclear region (Fig. 5k), an essential function for signalling
from Met9. The magnitude of effects of IQSEC1 depletion on
trafficking, however, were modest. We therefore turned to
potential effects on IQSEC1 in regulating signalling from Met.
IQSEC1-ARF signalling controls phosphoinositide generation
to induce invasion. We next examined whether the major effect
of IQSEC1-ARF5/6 on Met signalling is to contribute to Akt
activation. Generation of PI(3,4,5)P3 (PIP3) from PI(4,5)P2 is an
essential event in the Akt signalling cascade, allowing PIP3-
dependent recruitment of Akt to the cortex, PIP3-dependent
PDPK1 phosphorylation of Akt T30851 and the PIP3-dependent
release of SIN1 from RICTOR to allow Akt S473 phosphoryla-
tion52. PIP3 generation requires the sequential action of PI4-
kinases (PI4K), PIP5-kinases (PIP5K), and PI3-kinases (PI3K) to
convert PI to PIP3. All ARF GTPases can recruit and activate
PIP5Ks53–55, the latter of which there are three isoforms,
PIP5K1A–C (PIP5K1α/β/γ). ARF6 can activate PI3K signalling in
melanoma56 and function to recruit PIP5K1α to Met57. We
examined whether IQSEC1-ARF controls Akt activation by reg-
ulating PI(4,5)P2 production as a precursor to PIP3 generation.
We investigated the relationship between cell shape and PIP
level and localisation using biosensors and antibodies to each
lipid. We examined the ratio of lipid biosensor at the cell
periphery, which includes a region of ~4 μm at or very close to
the cell surface, to total expression. Accordingly, this analysis will
only detect bulk general PIP ratios in the peripheral region, and
not potential complex microtopologies of the cell membrane,
which may contain subdomains with different PIP compositions.
This analysis revealed that bulk general peripheral PI(4,5)P2 levels
were not different between cell shape classes (spindle, spread,
round) (Supplementary Fig. 7a, b). In contrast, bulk peripheral
PIP3 was elevated in both spindle and spread shapes, but with
alternate distributions. Spread cells had the highest bulk
peripheral PIP3 levels, which was uniformly peripheral. In
contrast, though spindle cells displayed lower bulk peripheral
PIP3 than spread cells, bulk peripheral PIP3 could be particularly
noted in regions of protrusions in 2D and 3D (Supplementary
Fig. 7a–f). This suggests that, at least at level of bulk analysis, a
Fig. 3 IQSEC1 activates ARF5/6 in distinct locations within protrusions. a Western blot of cells expressing Scr, ARF5 or ARF6 shRNA using anti-ARF5,
ARF6 and GAPDH (loading control) antibodies. ARF intensity normalised to Scr quantified. Mean ± s.d., n= 3 independent experiments. p-values, one-way
ANOVA. **p≤ 0.01. b and c Phase images of acini (mVenus positive, yellow) described in (a). Scale bars, 100 μm. Heatmap, area and compactness
measurements Z-score-normalised to control. p-values; one-way ANOVA, greyscale values as indicated. n= 3 independent experiments, 5 replicates/
condition, 2880–3188 acini/condition in total. Cartoon, acini phenotype representative of each condition. d Western blot of cells co-overexpressing (OX)
mNeonGreen (mNG) and TagRFP-T (RFP) or ARF5-mNG and ARF6-RFP (ARF5/6), and Scr or IQSEC1 KD4 shRNA. Anti-IQSEC1, ARF5, ARF6 and GAPDH
(loading control for ARF5) antibodies used. n= 2 independent experiments. e and f Phase images of acini described in (d). Scale bars, 100 μm. Heatmap,
area and compactness measurements Z-score-normalised to control. p-values, one-way ANOVA, greyscale values as indicated. n= 2 independent
experiments, 4 replicates/condition, 1254–1567 acini/condition in total. g Cells co-overexpressing ARF5-mNG and ARF6-RFP (ARF5/6 OX) were stained for
IQSEC1 v2. Merged and magnified image of spindle cell shown. Arrowheads, colocalization. n= 3 independent experiments. Scale bars, 20 μm. h Acini
expressing ARF5-mNG or ARF6-mNG were stained for IQSEC1 (FIRE LUT). Yellow and white arrowheads, colocalization in juxtanuclear region and protrusive
tips, respectively. Arrows, lack of colocalization. n= 3 independent acini imaged. Scale bars, 5 μm. i Schema, GTPase cycle, site of action of NAV-2729, QS11
and GTP-loaded ARF detection by GGA1-NGAT. j Acini expressing ARF5-mNG or ARF6-mNG and GGA1-NGAT-RFP were fixed and FIRE LUT of maximum
projections and a single Z-slice is shown. Arrowheads, colocalization in protrusions, arrows, colocalization in cell body. n= 2–5 independent acini imaged.
Scale bars, 10 μm. k and l Cells expressing GGA1-NGAT and k ARF5-NG or l ARF6-NG were transfected with Scr or IQSEC1 KD4 shRNA then treated with
NAV-2729 or QS11. % overlap of ARF and ARF-GTP probe/cell is shown in box-and-whiskers plot: 10–90 percentile; +mean; dots, outliers; midline, median;
boundaries, quartiles. n= 2 independent experiments, 3 replicates/condition with k 541–1287 and l 390–798 cells quantified/condition. p-values, one-way
ANOVA. *p≤ 0.05, **p≤0.01, ***p≤ 0.001 and ****p≤ 0.0001. m Schema, localisation of IQSEC1 and active ARFs in protrusions.
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combination of level and asymmetry of PIP3 promotes invasive
function (Supplementary Fig. 7d).
To align total levels of PIPs with analysis of bulk peripheral
distribution we validated that anti-PIP antibodies detected total
cellular PIP levels, observing they are responsive to PI3K
inhibition (LY294002) or activation (using myristoylated PI3K)
(Supplementary Fig. 7g–i). In contrast to PI3K inhibition, which
decreases total and bulk peripheral levels of PIPs (Supplementary
Fig. 7h, j), IQSEC1-depleted cells displayed an overall increase in
total PI(4,5)P2 and PIP3 levels (Supplementary Fig. 7k), con-
comitant with a decrease in bulk peripheral PIPs (Figs. 6a, S7c)
and the appearance of PIPs in intracellular compartments
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(Supplementary Fig. 7a). This reduction of bulk peripheral PIP3,
in the absence of IQSEC1 was observed equivalently whether the
cell cortex was defined using either F-actin or a cytoplasmic stain
(CellMask) (Supplementary Fig. 7l), and irrespective of cell shape
(Supplementary Fig. 7l), representing that bulk differences in PIP
levels were not simply a consequence of altered shape. Reduced
bulk peripheral PIP3 levels in IQSEC1-depleted was comparable
to the magnitude of PI3K-inhibited cells (Supplementary Fig. 7j).
These data suggest that IQSEC1-ARF-PIP5K is not essential for
general PI(4,5)P2-PIP3 generation, but rather that a
LRP1–Met–IQSEC1 v2 complex promotes bulk peripheral PIP3
production that leads to invasive protrusion formation (S7d, g).
IQSEC1 v2 promotes single cell spindle shape (Supplementary
Fig. 2d) and 3D invasion (Fig. 2e, f), while IQSEC1 v4 promotes
round cell shape. No difference in bulk peripheral PI(4,5)P2 levels
between cell shape classes (spindle, spread, round) was observed
(Supplementary Fig. 7a, b). Accordingly, rescue of IQSEC1
depletion with either IQSEC1 v2 or v4 partially restored total PI
(4,5)P2 levels to those observed in control cells (Supplementary
Fig. 7m). In contrast, the invasion-inducing IQSEC1 v2 supported
more robust activation of PIP3 generation than could IQSEC1 v4
(Supplementary Fig. 7m). Given that IQSEC1 v2 induces a switch
to spindle shape, this suggests that IQSEC1 v2-directed bulk
peripheral production of PIP3 drives invasion.
We next examined the components of PIP3 generation that
drive invasion. Isotype-selective Class I PI3K inhibitors revealed
that either PI3Kβ or PI3Kδ inhibition decreased pAkt levels,
while PI3Kα or PI3Kγ inhibition paradoxically increased pAkt
levels (Supplementary Fig. 8a). However, only PI3Kβ or Akt
inhibition significantly attenuated 3D growth and invasion
(Supplementary Fig. 8b–d). Depletion of PIP5K1A-C revealed
that PIP5K1β depletion showed the most robust decrease in
growth, invasion, and pAkt levels (Supplementary Fig. 8e–g).
These data suggest a PIP5K1β→ PI3Kβ→Akt pathway for 3D
growth and invasion.
Our data suggest that IQSEC1-ARF5/6 controls the PIP
production required for PIP5K1β→ PI3Kβ→ Akt signalling
during invasion (Supplementary Figure 7e). We tested whether
generalised cortical targeting of this PIP-Akt pathway could
overcome the need for IQSEC1 (Fig. 6b). We targeted each of
PIP5K1β, PI3Kβ, Akt1 to the cortex through addition of a
myristoylation sequence, and inhibited IQSEC1 by shRNA or
chemical means (NAV-2729) (Fig. 6b, c).
Myristoylation of PI3Kβ (PI3Kβmyr) or PIP5K1β (PIP5K1β-
myr), but not PIP5K1α (PIP5K1αmyr), increased Akt phosphor-
ylation, 3D growth and invasion, with the most robust increase
occurring upon PI3Kβmyr expression (Fig. 6c–f). As expected in
control cells, IQSEC1 depletion reduced pAkt levels and
attenuated 3D growth and invasion (Fig. 6c–f). Myristoylation
of PI3Kβ (PI3Kβmyr) or PIP5K1β (PIP5K1βmyr), but not PIP5K1α
(PIP5K1αmyr), increased 3D growth and invasion with the most
robust increase occurring upon PI3Kβmyr expression (Fig. 6c, e,
f). Strikingly, IQSEC1 perturbation (shRNA, NAV-2729) had a
disproportionate effect on invasion versus growth. While growth
was blunted, in IQSEC1-perturbed conditions invasion was
abolished (Fig. 6c, e, f). NAV-2729 treatment blocked the ability
of all cells in 3D to become acini. Single cells initially increased
slightly in area and adopted irregular shapes, manifested in
increased compactness, but not in invasion. Thus, generalised
cortical recruitment of PIPK signalling is sufficient to drive
growth, but not invasion. Invasion requires IQSEC1-dependent
ARF activity at invasive protrusions (Fig. 6i).
IQSEC1-ARF regulates localisation and activation of Akt. Akt
signalling showed a different influence on 3D behaviours than
that observed for PI3Kβ or PIP5K1β. Our data suggest that
IQSEC1 may contribute to Akt S473 levels by at least two
mechanisms: influencing PIP5K1β-directed PI(4,5)P2 production,
and interaction with RICTOR-SIN1 (Supplementary Fig. 7e).
While IQSEC1 depletion lowered endogenous pAkt levels,
expression of myristoylated Akt1 (Akt1myr) overcame the
requirement of IQSEC1 for pS473 phosphorylation (Fig. 6d, g, h).
As predicted, general cortical targeting of Akt1myr robustly
increased 3D area compared to control cells, but not invasion
(Fig. 6g, h). Strikingly, although Akt1myr no longer required
IQSEC1 for phosphorylation events normally indicating ‘active-
ness’ (i.e. pS473-Akt, Fig. 6d), IQSEC1 depletion still reversed the
Akt1myr -induced 3D growth increase to levels below control
cells, and abolished invasion; NAV-2729 was similarly an inhi-
bitor of these processes (Fig. 6g, h). Thus an effector of PIP3
signalling, Akt, requires IQSEC1 for full signalling output.
As experimentally ‘active’ Akt (asymmetrically cortically
targeted Akt1myr; as defined by pS473 levels) was unable to
induce oncogenic signalling in IQSEC1-depleted cells we
examined whether this was due to altered Akt localisation. In
2D, pAkt localised to cortical regions and to puncta distributed
through the cytoplasm (Supplementary Fig. 8h). In 3D, a pool of
pAkt was enriched in protrusion tips (Supplementary Fig. 7f,
white arrowheads), as well as to puncta throughout the
protrusion and acinus body. In contrast, IQSEC1-depleted cells
displayed an increased cortical pAkt aggregate size, but with
strongly reduced intensity (Supplementary Fig. 8h–k). These data
Fig. 4 IQSEC1 is a scaffold for Met signalling. a Schematic, IQSEC1 chimeras and variants display distinct phenotypes in 3D culture. GFP-trap
immunoprecipitation was performed on PC3 cells expressing these proteins followed by tryptic digestion “on-beads” and LC/MS/MS analysis. IQSEC1
domain-specific interactions were identified and sorted by mRNA expression compared in paired PC3 subclones. b STRING network analysis of IQSEC1-
binding partners identified by MS visualised using Cytoscape. Most IQSEC1-binding partners could be clustered into 8 protein complexes (colour coded).
c Schema, indicates the protein complex each binding partner is associated with. Heatmap shows the fold change of IQSEC1 interactors from panel
b binding to different IQSEC1 domains over GFP control. Values are −log2(FC), very high=−7 to −5, high=−5 to −2.5, medium −2.5 to −1, low=−1 to
−0.05, no binding >0.05. p-values; one-way ANOVA, greyscale values as indicated. The specific IQSEC1 domain to which each interactor binds is also
depicted. Interactions were sorted according to the fold change in mRNA of non-invasive PC3 subclones (GS689.Li, EMT) compared to invasive subclones
(PC3E, Epi) (RNAseq). d GFP-trap immunoprecipitation was performed on cells expressing GFP, GFP-IQSEC1 v2 or v4. Western blot analysis was carried
out using anti-Met, LRP1, GFP, IQSEC1 and GAPDH (loading control for the LRP1) antibodies. Quantitation of LRP1/IQSEC1 and Met/IQSEC1 interactions for
each GFP-trap are shown. Mean ± s.d., n= 3 and n= 4 independent experiments, respectively. p values, one-way ANOVA. **p≤ 0.01 and n.s. not
significant. e Cartoon, depicts domain-specific binding of IQSEC1 interactors. f PC3 acini expressing ARF5-mNG or ARF6-mNG were stained for Met
and LRP1. FIRE LUT images are displayed with magnified images shown in lower panels. White arrowheads indicate localisation in protrusion tips. n= 4
independent acini imaged. Scale bars, 5 µm (upper) and 10 µm (lower). g Schema, colocalization of IQSEC1-ARF interactors in protrusive tips. h and i Phase
images of PC3 acini expressing Scr, LRP1_1, Met_2, SORL1_1, RICTOR_1 or SIN1_2 shRNA. Scale bars, 100 μm. Heatmap, area and compactness
measurements Z-score-normalised to control. p-values, one-way ANOVA, greyscale values as indicated. n= 2 independent experiments, 4 replicates/
condition, 700–2400 acini/condition in total. Cartoon, depicts acinus phenotype representative of each condition.
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reveal that IQSEC1 is required for the signalling from, and
asymmetry of, the PIP3 effector Akt.
IQSEC1 regulates growth and invasion in vitro and in vivo.
Our data indicate that LRP1-Met-IQSEC1-promoted enrichment
of ARF5/6-dependent PIP3 signalling to induce invasion rather
than growth. We tested the generalisability of IQSEC1 inhibition
to inhibit growth and invasion mechanisms in commonly used
prostate cancer models. mRNA expression and western
blotting indicated that, with the exception of LRP1 in 22Rv1, all
components of the LRP1-Met-IQSEC1-ARF5/6 pathway are
expressed in examined prostate cancer cell lines (Supplementary
Fig. 9a, b).
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Chemical inhibition (NAV-2729, Supplementary Fig. 9c–h) or
genetic depletion (Supplementary Fig. 10a–f) of IQSEC1
attenuated growth and/or invasion in a range of 3D cancer cell
models. This included upon ectopic OX of the LRP1–IQSEC
complex in cells with low endogenous levels (LRP1TM-GFP in
22Rv1, GFP-IQSEC1 v2 in DU145), HGF treatment of the mixed
morphology DU145 cultures to resemble the spindle-type
invasion of PC3 (Supplementary Fig. 9, S10), highly invasive
human breast cancer cells (MDA-MB-231), murine pancreatic
ductal adenocarcinoma cells (PDAC; KC-PTEN, K-rasG12D/
PTEN-null58) and patient-derived PDAC cells (TKCC-07)
(Supplementary Fig. 10a, c–f). Thus, IQSEC1 is required for
growth and invasion across a number of 3D cell models from
different cancer types.
We examined the in vivo role of IQSEC1 by intraprostatic
xenograft of IQSEC1-depleted PC3 cells (Fig. 7a). While
IQSEC1 depletion did not significantly attenuate tumour
incidence, tumour area and volume were significantly reduced
(Fig. 7b–e). As predicted from our 3D in vitro studies, metastatic
activity was strongly decreased in IQSEC1-depleted cells. Both
the incidence and number of macrometastases were significantly
decreased in IQSEC1-depleted cells (Fig. 7f, g). Wide-spread
dissemination of macrometastases was observed in controls
cells. In the few mice presenting macrometastases in IQSEC1-
depleted cells, these were limited to prostate proximal lymph
nodes (with the exception of a singular diaphragm-located
tumour) (Fig. 7h), and showed no difference in proliferation or
apoptosis to controls, confirming a bona fide effect on move-
ment (Fig. 7i, j). These data indicate an essential requirement for
IQSEC1 in metastasis in vivo.
Elevation in IQSEC1, ARF5 and ARF6 levels was associated
with clinical outcome in prostate cancer across 12 studies,
representing 2910 patients (Fig. 8a). Increased Copy Number
(CN) of IQSEC1 occurred most frequently in advanced prostate
cancers (Fig. 8b, CR, castrate-resistant; NE, neuroendocrine),
associated with a gain in 3p Status (Fig. 8c; IQSEC1, 3p25.2-25.1).
Primary prostate tumours with elevated IQSEC1 were of
significantly higher grade (Fig. 8d), were associated with
tumour-bearing lymph node positivity (Fig. 8e) and metastases
(Fig. 8h). Mirroring the ablation of wide-spread metastasis of
IQSEC1-depleted PC3 xenografts (Fig. 7h), IQSEC1 increase
occurred most frequently in samples from diverse metastatic sites,
but particularly bone, liver and lymph node (Fig. 8g). IQSEC1
increase occurred exclusively with androgen deprivation therapy,
retained presence of tumour after therapy, and increased levels of
the androgen receptor V7 variant, a major mechanism for escape
from androgen deprivation (Fig. 8h–j). A clinical indicator of
disease, serum PSA levels, was elevated in patients displaying
combined IQSEC1 and ARF5/6 elevation (Fig. 8k). This suggests
a clinical association of IQSEC1–ARF5/6 gain with therapy
resistance and metastasis.
We examined the association of IQSEC1, ARF5, and ARF6
elevation with frequent genomic alterations in prostate cancer.
IQSEC1 increase was associated with amplifications particularly
in AR and MYC and to a lesser extent with loss of PTEN, and
prominently with TP53 mutation, but not common gene fusion
events (Fig. 8l–n, S11a). ARF6 increase followed a similar profile,
while ARF5 increase was associated with a broader range of
mutational events. IQSEC1 allowed robust stratification of
prostate cancer patients, stratifying a 24-month decrease in
median overall survival in IQSEC1-elevated patients (Fig. 8o, 665
patients). Inclusion of ARF5/6 increase did not change the
median overall survival of this group, but rather extended the
median survival of the control arm, resulting in a 35-month
survival difference compared to the IQSEC1-ARF5-ARF6 ele-
vated group. IQSEC1 increase was similarly associated with TP53
mutation and MYC amplification across the pan-cancer The
Cancer Genome Atlas (TCGA) dataset, representing 10,449
patients (Supplementary Fig. 11a–d). Strikingly, IQSEC1, ARF5
and ARF6 increase similarly stratified patient survival when all
tumour types were considered together, providing an exceptional
>9-year (111 months) median survival increase for non-IQSEC1-
ARF5/6-amplified patients (across 9307 patients) (Fig. 8p).
Comparison of matched normal–tumour tissue from the
TCGA prostate cohort (n= 52) showed a significant increase in
overall IQSEC1 mRNA in tumours (Fig. 8q). This was
accompanied by a switch from the non-invasive IQSEC1 v1
isoform, to the pro-invasive IQSEC1 v2 in tumours (Fig. 8r).
Analysis of the pan-cancer TCGA dataset for tumour types with
profiled normal tissue revealed that four tumour types (kidney,
KICH; liver, LIHC; prostate; sarcoma, SARC) displayed IQSEC1
mRNA higher than normal tissue (Fig. 8s). However, seven
tumour types showed that rather than an increase in overall
IQSEC1, instead tumours underwent an isoform switch from v1-
to-v2 (Fig. 8s). This demonstrates that isoform switching to
IQSEC1 v2 is a major event associated with tumourigenesis in
patients.
Finally, we examined the association of IQSEC1 mRNA levels
across the pan-cancer TCGA dataset with common tumour-
associated signalling pathways from reverse phase protein array
Fig. 5 IQSEC1–LRP1 complex regulates Met endocytic trafficking. aWestern blot of cells co-expressing mNG and RFP or ARF5-mNG (Control) and ARF6-
RFP (ARF5/6) with Scr or IQSEC1 KD4 shRNA. Anti-IQSEC1, phospho-Y1234/1235 Met, Met, phospho-S473 Akt, Akt, and GAPDH (sample control)
antibodies used. b Quantitation of phospho/total Met and phospho/total Akt expression is presented as signal intensity relative to control. Mean ± s.d.,
n= 3 independent experiments. p values; one-way ANOVA. c Schema, effect of IQSEC1 on Met trafficking. d Cells expressing Scr or IQSEC1 KD4 shRNA
were incubated with a Met-647 antibody (4 °C) (Surface) then stimulated with HGF (Internalisation). Chloroquine was added to allow accumulation of
surface-derived Met (black) (1 h, 17 °C) prior to HGF stimulation (Recycling). Cells were stained with F-actin (green, outlines) and Hoechst (nuclei,
magenta). Magnified images are inset. Scale bars 20 µm. e Intensity of Met/cell was quantified (Z-score normalised); shown in box-and-whiskers plot:
10–90 percentile; + mean; dots outliers; midline median; boundaries, quartiles. n= 2 independent experiments, 4 replicates/condition, 421, 546, 122, 126,
93, 120, 150, 136, 219 and 282 cells quantified in total. p values: Welsh’s 2-tailed t-test. f Line graphs show relative regional intensities compared to whole
cell intensity of Met staining (Z-score normalised). Mean ± s.e.m., n= 2 independent experiments, 4 replicates/condition, 421, 122, 93, 150 and 219 (Scr)
and 546, 126, 120, 136, and 282 (IQSEC1 KD4) cells quantified in total. p values: Welsh’s 2-tailed t-test. g Schema, sub-cellular re-localisation of active Met
upon HGF treatment. h Cells expressing Scr, IQSEC1 KD4, LRP1 or SORL1 shRNA were stimulated with HGF then stained for phospho-Met (black), F-actin
(green, outlines) and Hoechst (nuclei, magenta). Magnified images are shown. Arrows, reduction of pMet in periphery. Scale bars 20 µm. Cartoon, sub-
cellular localisation of active Met. i and j Quantitation of spot intensity (Z-score normalised) is shown for images in (h) in box-and-whiskers plot: 10–90
percentile; +mean; dots outliers; midline median; boundaries quartiles. i n= 7 independent experiments, 3 replicates/condition, 3519–5185 cells/condition
and j n= 2 independent experiments, 4 replicates/condition, 239–988 cells/condition. p-values; one-way ANOVA. k Schema, regulation of Met
internalisation, but not recycling, by IQSEC1 and LRP1. All p values; n.s. not significant, *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 and ****p≤ 0.0001.
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(RPPA) data. Within each cancer type IQSEC1 expression was
divided into high and low using a median split of mRNA levels,
and protein differences between each group that consistently and
significantly trended in the same direction across a quarter of all
cancer types was calculated (Supplementary Fig. 11e). Mirroring
IQSEC1 regulation of phosphoinositide signalling in PC3 cells, a
clear PI3K-AKT signature was associated with high IQSEC1
levels across ten tumour types (Fig. 8t). Together, these data
indicate a role for tumour-associated isoform switching to
IQSEC1 v2 to promote PI3K-AKT signalling and metastasis
across cancer types, resulting in treatment resistance and a robust
decrease in patient survival.
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Discussion
Our results clarify a long-held conundrum of how the same
signalling pathways lead to distinct biological outputs: alternate
isoforms of the same RTK effector, IQSEC1, differentially localise
to control ARF GTPase-dependent phosphoinositide metabolism
at these distinct locales.
We describe that IQSEC1 is a key regulator of bulk peripheral
PIP3 signalling to promote invasion. Our data support a model
whereby pro-invasive IQSEC1 isoforms form a complex with the
HGF receptor Met and the endocytic receptor LRP1 at mem-
branes that will develop into invasive protrusions (Fig. 7k).
IQSEC1 activates GTP loading on ARF6 to (1) stimulate PIP5K-
mediated PI(4,5)P2 production, which is (2) a precursor to PI3K-
mediated PIP3 production to (3) promote invasive protrusion
formation. Elevation of bulk PIP3 levels also triggers cell growth,
concomitant with internalisation of Met and (4) activation of
pAkt downstream of the mTORC2 complex. Met and pAkt are
retrograde transported in the body of protrusions on ARF5
endosomes to a juxtanuclear signalling compartment, essential for
growth and invasion. Inhibiting this IQSEC1-mediated ARF5/6
activation abolishes the collective growth and invasion/metastasis
in vitro and in vivo.
Multiple isoforms of IQSEC1 exist through combination of
alternate start sites and alternate splicing, though the regulators of
these events are unknown. Such N-terminal and C-terminal
extensions operate in a hierarchy; N-terminal extensions provide
association with endocytic co-receptors LRP1 and SORL1, while
alternate C-termini can either positively or negatively enhance
invasive activity. SORL1 and LRP1 are members of the LDLR
family, co-receptors involved in endocytic control of a milieu of
processes41. SORL1 and LRP1 shared the same N-termini binding
region, were anti-correlated in their expression between invasive
and non-invasive cells, and possessed antagonistic effects on
invasion. This supports a notion that the function of IQSEC1 is
highly contextual, dependent on not only which IQSEC1 tran-
script is expressed, but also the repertoire of potentially compe-
titive interactors expressed. It is notable switching to the pro-
invasive IQSEC1 v2 occurs in at least a quarter of all sampled
tumour types, suggesting this may be a major mechanism
underpinning tumourigenesis.
LRP1 is a multifunctional endocytic receptor involved in a
number of biological functions41. We report this as a crucial pro-
invasive partner of IQSEC1 and Met. Endogenous LRP1 and Met
were found in a complex irrespective of IQSEC1, suggesting that
IQSEC1 binds an existing complex to couple their endocytic
itinerary. This likely also requires the function of the extracellular
cleaved 515 kDa fragment of LRP1, as the transmembrane frag-
ment alone is insufficient to drive invasion when expressed
ectopically. LRP1 may help generate PIP3 during invasion
through its ability to form an LRP1–Rab8a:GTP–PI3K complex,
to control Akt signalling on endosomes, as it does in other
contexts59.
The role of phosphoinositides, particularly PIP3, in regulating
leading edge formation or protrusion activity has been extensively
reported60–67, including ARF6 being a driver of PI3K enrichment
in melanoma cell protrusions57. Our data further supports central
roles for ARF GTPases in invasion. Protrusive invasion requires a
discrete pool of protrusive activity concomitant with global
inactivity in surrounding regions, akin to pushing out from single
point inside a balloon rather than simultaneously from all sur-
faces. IQSEC1 v2 localised with Met and LRP1 and promoted
elevation in bulk PIP3 production resulting in invasive protru-
sions. Such exquisite spatial enrichment may explain why the
most prominent peripherally recruited IQSEC1 isoform (v4) fails
to induce robust invasion, and perhaps why we see significant, but
modest global GTP loading changes in ARF5/6 upon IQSEC1
depletion. The identity of invasion-specific PIP3 effectors remains
to be demonstrated, but one likely candidate is Rac1, which is
dependent on PIP3 for activation68.
Why are both ARF5 and ARF6 required? Although ARF5
phenotypes most closely mimicked that of IQSEC1, there was still
a dependency on ARF6. ARFs can act in pairs69, and our data
suggests that ARF5/6 may act at sequential steps: ARF6 at the
cortex, and ARF5 in endosomes. It is interesting to note that
previously described fast-cycling mutants of either ARF35 were
unable to induce collective morphogenesis like WT ARFs, sug-
gesting that precise control over GTP cycling is essential for col-
lective invasion. Indeed, a key effector identified was ARFGAP1,
which in our hands functioned as an effector rather than an
antagonist of ARF signalling, similar to the dual effector termi-
nator function described for other ARFGAPs46–48. That this GAP
associates with the GEF supports the notion of tight control over
GTP cycling. Whether ARF5/6 both, or separately, interact with
the two identified effectors (ARFGAP1, PIP5K1β), is unclear.
The ARF GTPase-dependent recycling of Met promotes sus-
tained ERK signalling required for migration in other cells57,70.
Internalisation of Met is key to full oncogenic output8,9. IQSEC1
has modest effects on internalisation and juxtanuclear trafficking
of Met, suggesting the major role of IQSEC1 is to couple Met to
its downstream component Akt. Met recycling was not perturbed
in IQSEC1-depleted cells, suggesting another ARFGEF may
promote this function. The PI(4,5)P2/PIP3-dependent Cytohesin-
1 ARFGEF is one candidate for this, as we note upregulation in
PC3, and it is required downstream of Met for invasive activity
in other cells71. Cytohesin-1 alternate splicing controls its
recruitment to membranes by controlling differential affinity for
Fig. 6 IQSEC1-ARF signalling controls phosphoinositide generation during invasion. a Quantitation of PI(4,5)P2 or PIP3 in the presence or absence of
IQSEC1 is shown in box-and-whiskers plot: 10–90 percentile; + mean; dots outliers; midline median; boundaries quartiles. Values, peripheral/total
intensity/cell, n= 3 independent experiments, 4 replicates/condition, 1674/1959 (Scr and IQSEC1 in upper panel) and 2684/2083 (Scr and IQSEC1 in lower
panel) cells quantified. p-values; one-way ANOVA. ****p≤ 0.0001. b Cartoon, PIPK targeting in presence or absence of IQSEC1. cWestern blot of PC3 cells
expressing Myr-FLAG-Cre (Control), Myr-FLAG-PIP5Kα, Myr-FLAG-PIP5Kβ or Myr-FLAG-PI3Kβ and either Scr or IQSEC1 shRNA (KD4). Anti-IQSEC1,
phospho-S473 Akt, total Akt and GAPDH (loading control for IQSEC1) antibodies were used. n= 2 independent experiments. d Western blot of PC3 cells
expressing Myr-FLAG-Cre (Control) or Myr-Akt1 and either Scr or IQSEC1 KD4 shRNA using anti-IQSEC1, phospho-S473 Akt, total Akt and GAPDH
(loading control for IQSEC1) antibodies. n= 2 independent experiments. e and f Phase images of PC3 acini described in (c) are shown. Scr acini were also
treated with NAV-2729 (IQSEC1 inhibitor). Scale bars, 100 μm. Heatmap, area and compactness measurements Z-score-normalised to control. p-values;
one-way ANOVA, greyscale values as indicated. n= 3 independent experiments, 4 replicates/condition, 1693–2435 acini/condition in total. Cartoon, acini
phenotype representative of each condition. g-–h Phase images of PC3 acini described in (d) are shown at 96 h. Scr acini were treated with IQSEC1-
inhibiting compound NAV-2729. Scale bars, 100 μm. Heatmap, area and compactness measurements Z-score-normalised to control. p-values; one-way
ANOVA, greyscale values as indicated. n= 2 independent experiments, 4 replicates/condition, 1287–2363 acini/condition in total. Cartoon, acini
phenotype representative of each condition. i Schema, summarises the relationship between location and level of peripheral PIP3 and 2D and 3D PC3
phenotype.
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PI(4,5)P2 or PIP372,73. Such a GEF would likely act subsequently
to IQSEC1-directed control of peripheral PI(4,5)P2 levels. Thus,
IQSEC1 may sit at the top of a cascade of ARF GEFs controlling
Met endocytosis, recycling, and signal output. This may explain
why IQSEC1 inhibition alone can reverse ARF5/6 OX, despite co-
expression of numerous ARFGEFs in PC3 cells.
A striking result is that although IQSEC1-ARF5/6 would
classically be considered ‘upstream’ of PI(4,5)P2, PIP3, and Akt,
inhibition of IQSEC1 nonetheless counteracts the experimental
activation of this pathway at multiple levels. Our data suggests
that this is due to alternate isoforms of IQSEC1 possessing dif-
ferent locations, thereby likely influencing where downstream
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ARF-dependent PIP production can occur. We note that our
analysis approaches for PIP localisation at the periphery detects
only bulk location of the PIP, and does not allow for detection of
discrete subdomains containing different PIPs that may occur
because of microtopologies of the cell surface. It remains to be
demonstrated exactly how this IQSEC1-ARF module may control
PIP metabolism spatially at the cell surface.
Critically, we demonstrate that IQSEC1 inhibition blocks
growth and invasion in a multitude of in vitro 3D models across
several cancer types, and tumour growth and metastasis in vivo.
Elevated IQSEC1 expression is associated with clinical metrics of
poor outcome: higher-grade tumours, metastasis, treatment
resistance, PI3K pathway activation. Consequently, IQSEC1-
ARF5/6 stratifies long-term recurrence-free survival in prostate
cancer and more generally across a number of tumour types.
In conclusion, we identify a molecular mechanism that allows
cells to determine whether to grow or invade in response to
activation of an RTK: alternate isoforms of an effector protein,
IQSEC1, differentially localise to modulate signalling to phos-
phoinositide signalling pathways.
Methods
Cell culture. PC3 (ATCC), PC3 E-Cad+, TEM4–18, TEM2–5, GS689.Li, GS694.
LAd, GS683.LALN, JD1203.Lu, GS672.Ug (M. Henry, University of Iowa), PC3-Epi
and PC3-EMT (K. Pienta, Johns Hopkins School of Medicine) and LNCaP cells (H.
Leung, Beatson Institute) were cultured in RPMI-1640 supplemented with 10%
foetal bovine serum (FBS) and 6 mM L-glutamine. RWPE-1, RWPE-2, WPE-NB14
and CA-HPV-10 cell lines (ATCC) were grown in keratinocyte serum free media
(K-SFM) supplemented with 50 μg/ml bovine pituitary extract (BPE) and 5 ng/ml
epidermal growth factor (EGF). DU145 cells (ATCC) were maintained in mini-
mum essential medium (MEM) supplemented with 10% FBS and 6 mM L-gluta-
mine. VCaP, MDA-MB-231 (ATCC), murine KC Ptenfl/+58 (J. Morton, CRUK
Beatson Institute) and TKCC-07 cells were cultured in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% FBS and 6mM L-glutamine. The
TKCC-07 cells used in this project were provided by the Australian Pancreatic
Cancer Genome Initiative (APGI) at the Garvan Institute of Medical Research
(www.pancreaticcancer.net.au). 22Rv1 cells (H. Leung, Beatson Institute) were
grown in phenol free RPMI-1640 containing 10% charcoal stripped FBS and 6 mM
L-glutamine. HEK293-FT (Thermo Fisher Scientific) were cultured in DMEM with
10% FBS, 6 mM L-glutamine and 0.1 mM non-essential amino acids (NEAA) (all
reagents from Thermo Fisher Scientific).
Growth factors or inhibitors were added as follows; 50 ng/ml hepatocyte growth
factor (HGF) (PeproTech), 10 μM NAV-2729 (Glixx Laboratories), 10 μM QS11
(Tocris), 100 μM chloroquine (CST), 20 μM SecinH3 (Tocris), 25 μM
cycloheximide (Sigma), 1 μM LY-294002 (Merck), 1 μM AZD8835 (AstraZeneca),
0.1 μM AZD8186 (AstraZeneca), 1 μM AS-6052-40 (Stratech), 1 μM Cal-101
(Stratech), and 10 μM AktII (Calbiochem) inhibitors.
Cells were routinely checked for mycoplasma contamination. PC3, RWPE-1
and RWPE-2 cells were authenticated using short tandem repeat (STR) profiling.
Generation of stable cell lines. Cell lines were made by co-transfecting plasmids
with lentiviral packaging vectors (VSVG and SPAX2) into packaging cells
(HEK293-FT) using Lipofectamine 2000 (Thermo Fisher Scientific). Viral super-
natants were collected; filtered using PES 0.45 μm syringe filters (Starlab) to remove
cell debris, and concentrated using Lenti-X Concentrator (Clontech) as per the
manufacturer’s instructions. Cells were then transduced with the lentivirus for
3 days before either FACS sorting or selection with 2.5 μg/ml puromycin, 300 μg/
ml G418 (both Thermo Fisher Scientific), 10 μg/ml blasticidin (InvivoGen) or
200 μg/ml hygromycin (Merck). Stable knockdown of proteins was achieved using
pLKO.1-puromycin, pLKO.1-hygromycin or pLKO.1-membrane tagged Venus
(substituted for puromycin) lentiviral shRNA vectors. ShRNA sequences are listed
in Supplementary Table 3. GFP-IQSEC1 v2 and GST-GGA3-GAT were kind gifts
from J. Casanova (University of Virginia). All RNAi-resistant variants and chi-
meras were made by mutagenesis or sub-cloning using fragment synthesis (Gen-
eArt). GFP ARFs were kinds gift from P. Melancon (University of Alberta) and
alternate fluorescent tags and mutations generated by sub-cloning. EGFP-PH-
GRP1 and EGFP-PH-PLCδ were described previously74 and sub-cloned into
mNeonGreen. Myr-FLAG-Cre, Myr-FLAG-PIP5Ks, Myr-FLAG-PI3Ks, Myr-Akt1
and RFP-GGA1-NGAT were purchased from Addgene. LRP1-EGFP was a kind
gift from S. Kins (Technical University Kaiserslautern).
IQSEC1 variant information. The nomenclature for IQSEC1 variants has been
complicated by alternate names for IQSEC1 in literature and changing isoform
designations at NCBI. Unification of nomenclature is presented in Supplementary
Table 4.
Live 3D culture and analysis. Culture of cell lines as 3D acini was adapted from
previous protocols5. Briefly, single cell suspensions were made (1.5 × 104 cells per
ml) in the appropriate medium supplemented with 2% growth factor reduced
matrigel (GFRM; BD Biosciences). 150 μl of this mix was plated per well in a 96-
well ImageLock plate (Essen Biosciences) pre-coated with 10 μl of GFRM for
15 min at 37 °C. Plates were incubated at 37 °C for 4 h, then imaged using an
IncuCyte® ZOOM (Essen BioScience) with Incucyte ZOOM Live Cell Analysis
System Software 2018A. Images were taken every hour for 4 days at 2 positions per
well using a ×10 objective lens. Sample size (n) and replicate number are stated for
each experiment in figure legends. Outlines of phase and GFP-positive (where
appropriate) acini were generated using a custom pipeline in CellProfiler (Version
3.1.8). A custom macro in Fiji software (2.0.0) was then used to colour code images
from each time point, progressively coloured along a blue-to-red rainbow time-
scale, and concatenate them into one image per 12-h block to reduce data
dimensionality of multiday imaging. Using CellProfiler, measurements such as area
and compactness, which could reliably measure size and protrusiveness of 3D PC3
objects, respectively, were generated for each 12-h block. Custom pipelines
designed in KNIME Data Analytics Platform (Version 3.3.1) were then used to
collate data from multiple experiments, normalise to controls, calculate Z-score and
perform statistical analysis using one-way ANOVA. Normalised data and p-values
are presented as heatmaps generated in PRISM 7 (GraphPad). The number of
independent experiments (n), technical replicates, and the number of acini
quantified per condition are stated in each figure legend.
2D and 3D acini immunofluorescence and imaging. 3D acini were set up as
described above in either eight-well coverglass chamber slides (Nunc, LabTek-II) or
in 96-well plates (Greiner) pre-coated with 60 or 10 μl GFRM respectively for
3 days. For 2D, cells were plated on a 96-well plate (Greiner) for 48 h prior to
fixation. Samples were washed twice with PBS and fixed in 4% paraformaldehyde
for 15 min. Samples were then blocked in PFS (0.7% fish skin gelatin/0.025%
saponin/PBS) for 1 h at RT with gentle shaking and primary antibodies added
overnight (1:100 unless stated otherwise) at 4 °C. After three washes in PFS, Alexa
Fluor secondary antibodies (1:200), HCS CellMask™ Deep Red Stain (1:50,000) or
Hoechst (1:1000) (all Thermo Fisher Scientific) were added for 45 min at room
temperature (RT). Samples were maintained in PBS, after three 5 min washes in
PBS, until imaging was carried out.
Cells or acini on chamber slides were imaged using a Zeiss 880 Laser Scanning
Microscope with Airyscan. Images taken in super resolution mode on the Airyscan
Fig. 7 IQSEC1 regulates growth and invasion in vivo and IQSEC1-ARF signalling is associated with poor patient outcome. a Schema, intraprostatic
transplantation of PC3 cells expressing either Scr or IQSEC1 KD4 shRNA into CD1-nude male mice. Tumour growth was determined after 8 weeks using
ultrasound and the incidence and location of macromets counted. b Graph shows prostate tumour incidence (in total number of mice) in mice transplanted
with PC3 cells expressing either Scr (control, 12 mice) or IQSEC1 KD4 shRNA (10 mice). p-values (Chi-squared): n.s. not significant. c Ultrasound images
show area and volume of representative prostate tumours in mice injected with PC3 cells expressing either Scr or IQSEC1 KD4. d and e The d area and
e volume of each prostate tumour detectable by ultrasound was measured. Values, mean ± s.d. p-values; Mann–Whitney test (2-tailed). *p≤ 0.05. Note
that one mouse in each condition had two primary prostate tumours. Control, 12 mice, 13 tumours and IQSEC1 KD4 shRNA, 10 mice, 11 tumours. f and
g Macrometastasis incidence was counted and is presented as (f) number of mice and (g) count per mouse, values, mean ± s.e.m. 12 and 10 mice were
transplanted with PC3 cells expressing Scr or IQSEC1 KD4 shRNA, respectively. p-values (Chi-squared and Mann–Whitney test (2-tailed) respectively):
*p≤ 0.05, **p≤ 0.01. h Heatmap shows the frequency at which metastasis occurred at locations with different proximity to the prostate. Cartoon,
summarises the locations metastasis was observed. i and j The (i) tumour and (j) lymph node (LN) sections were stained with anti Ki67 and Cleaved
Caspase 3 (CC3) antibodies and the percentage of positive cells quantified. Each mouse is represented by a differently coloured point on the bar graphs.
Values, mean ± s.e.m. Sections were taken from 6 (Scr) and 5 (IQSEC1 KD4) tumours and from 4 (Scr) and 2 (IQSEC1 KD4) lymph nodes. p-values;
Mann–Whitney test (2-tailed). n.s. not significant. k Schematic depicting the signalling mechanisms involved in IQSEC1 dependent model of prostate
cancer growth and invasion.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21847-4
16 NATURE COMMUNICATIONS |         (2021) 12:1623 | https://doi.org/10.1038/s41467-021-21847-4 | www.nature.com/naturecommunications
microscope were processed using the Zeiss proprietary ZEN 3.2 software, exported
as TIFF files and processed in Fiji. Cells or acini on 96-well plates were imaged
using an Opera Phenix™ high content analysis system and where appropriate
Harmony High-Content Imaging and Analysis Software (PerkinElmer, Version
4.6) was used to perform machine learning.
Antibodies used: Alexa Fluor 488 (A12379), 568 (A12380) or 647 (A22287)
phalloidin (Thermo Fisher Scientific), anti-IQSEC1 (Sigma, G4798), anti-IQSEC1
(Caltag-Medsystems, PSI-8009), anti-LRP1 (Sigma, L2295), anti-Met (CST, 3127),
anti-Met phospho 1234/1235 (CST, 3077), anti-Akt phospho S473 (CST, 3787),




















































































































































































































































































































































































Genetic Alteration Gain No alterations Cohort size
IQSEC1-ARF5/6
Alteration (% cases) 23551 124841 9 2314 306834
Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012) Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019) Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015) Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016)
Prostate Adenocarcinoma (Broad/Cornell, Cell 2013) Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012) Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016) Prostate Adenocarcinoma (MSKCC, Cancer Cell 2010)
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0192Z), anti-Cleaved Caspase 3 (CST, 9661), anti-PtdIns(3,4,5)P3 and anti-PtdIns
(4,5)P2 (Echelon Biosciences, Z-P345B and Z-P045).
2D and 3D phenotypic analysis of fixed samples. Harmony High-Content
Imaging and Analysis Software (PerkinElmer, Version 4.6) was utilised to perform
machine learning using a number of custom designed pipelines. For 2D mor-
phology assays the shape of each cell was defined by either F-actin or HCS Cell-
Mask staining and machine learning then used to classify cells as either spindle,
spread or round phenotypes. Each cell was imaged in three consecutive planes
(2 µm step size) and analysis was processed on each individual plane. Cells were
detected based on nucleus localisation and defined by either F-actin or HCS
CellMask staining. Cells in contact to the image border or without green channel
positive signal were discarded. The morphology properties of each object were
calculated to classify them into three different categories (‘round’, ‘spindle’ and
‘spread’) using machine learning following manual training. Different cell regions
were defined as (a) ‘peripheral’, using Method resize region [µm/px], region type
‘membrane region’, Outer border: −2 px (−1.194 µm), Inner border: 5 px
(2.985 µm), (b) ‘nucleus’, using method ‘Standard’ on nucleus region, (c) ‘cyto-
plasm’, using method ‘restrict by mask’: population ‘green cells’, mask regions
‘Peripheral’ and ‘Nucleus’. Finally, intensity properties of PIP probe channel (Alexa
488) were calculated by standard method in the different cell regions within each
object. As an alternate approach, images were also stack processed using maximum
projection all slices, followed by a similar pipeline as described above. No sig-
nificant difference was obtained between methods.
A custom pipeline was generated using KNIME Data Analytics Platform
(Version 3.3.1) to collate data, calculate the log2 fold change of each phenotype
over control and to calculate statistical significance using one-way ANOVA. Data
obtained from three different replicates was collected and combined with
experiment keys providing information about replicates and samples. For image
analysis using single plane stack processing, objects that were in more than one
plane were detected as a similar object using a similarity search of objects in
subsequent planes based on euclidean distance search of nearest neighbour and
distance selection using object X and Y positions. Upper bound (use range
checking) used was 5.0. Automated selection of one single plane per object based
on area (or alternatively, average of the three planes of the same object) was used
for subsequent analysis. Selection of samples to be analysed, followed by selection
of control sample, and log2 transformation of intensity data and normalisation to
control was followed. In some cases this analysis was carried out in sub-populations
of cells that either expressed a fluorescently tagged plasmid or were stained with a
specific antibody.
The use of the nuclear, cytoskeletal and cytoplasmic reagents described above
also allowed each cell to be segmented into specific sub-cellular regions i.e. nuclear,
cytoplasmic and peripheral (defined as 5 pixels from outer edge of cell). When used
in combination with fluorescently tagged proteins (such as reporters for
phosphoinositides) or antibodies the mean intensity of a specific protein per cell
(intensity/cell) or per sub-cellular region per cell (i.e. mean peripheral intensity/
mean total intensity/cell) could be measured. Where appropriate ‘spots’ of positive
staining were detected within these sub-cellular regions to more accurately
calculate the mean intensity/cell or mean spot area/cell.
Custom KNIME Data Analytics Platform (Version 3.3.1) pipelines described
previously74 were then used to collate data, to calculate the ratio over control and
to determine statistical significance. In addition, these pipelines were adapted to
measure total intensity of specific antibodies in 3D acini. Data are presented in box
and whiskers plots as z-score normalised or as log2 fold change over control where
each point represent one cell. The number of independent experiments (n),
technical replicates, number of cells/acini imaged per experiment, statistical test
performed and significance is stated in the appropriate figure legend.
Harmony High-Content Imaging and Analysis Software (PerkinElmer, Version
4.6) was also used to quantify the colocalization between mNeonGreen-tagged
ARF5 or ARF6 and RFP-GGA1-NGAT. PC3 cells stably expressing ARF/GGA1
were FACS sorted and a population that was positive for both mNeonGreen and
RFP selected. These cells were plated for 24 h then treated with either NAV-2729 or
QS11 overnight. Cells were then fixed, stained with CellMask (1:50,000) and
Hoechst (1:1000) and imaged using an Opera Phenix™. A custom pipeline was
created to identify red (GGA1+) and green (ARF+) ‘spots’ throughout each cell
and to calculate the percentage of green spot area that overlapped with red spot
area per cell. n= 2 with 4 replicates per condition with >500 cells imaged per
condition.
Animal studies. Animal experiments were performed in compliance with all
relevant ethical regulations and approvals of the relevant UK Home Office Project
Licence (70/8645) and carried out with ethical approval from the Beatson Institute
for Cancer Research and the University of Glasgow under the Animal (Scientific
Procedures) Act 1986 and the EU directive 2010, and sanctioned by Local Ethical
Review Process (University of Glasgow).
7-week-old CD1-nude male mice were obtained from Charles River (UK). Mice
were housed at ambient temperature (19–22 °C), with relative humidity of 45–65%,
and a 12 h–12 h light–dark cycle. 5 × 106 PC3 cells stably expressing either Scr (12
mice) or IQSEC1 KD4 (10 mice) shRNA were surgically implanted into one of the
anterior prostate lobes of each mouse75. The mice were continually assessed for
signs of tumour development and humanely sacrificed at an 8-week timepoint
when tumour burden became restrictive. Primary tumours were imaged and
tumour area and volume measured using VevoLAB ultrasound equipment and
VevoLAB 3.1.1 software. Significance was calculated using Mann–Whitney, *p ≤
0.05. Percentage of mice with tumours or with proximal (lumber lymph nodes and
epididymal fat pads) or distal (thoracic lymph nodes and lungs) metastases were
calculated by gross observation. p values were determined using a Chi-squared test
(with Fisher’s exact test) adjustment, n.s.= not significant, *p ≤ 0.05.
Immunohistochemistry (IHC). 4 µm formalin fixed paraffin-embedded (FFPE)
sections were cut from tissue blocks and maintained at 60 °C for 2 h. FFPE sections
were stained with Cleaved Caspase 3 (CST, 9661) and Ki67 (Abcam, ab16667)
antibodies using the Leica Bond Rx autostainer. Sections were loaded onto the
autostainer, de-waxed (Leica, AR9222) and epitope retrieval carried out. Both
antibodies were retrieved using ER2 buffer (Leica, AR640) for 30 min at 95 °C.
Sections were rinsed with Leica wash buffer (Leica, AR9590) before peroxidase
block was performed using an Intense R kit (Leica, DS9263). Caspase 3 was stained
at a previously optimised dilution of 1/500 and Ki67 at 1/100 before washing with
Leica wash buffer and then application of rabbit envision secondary (Agligent,
K4003) and visualised using DAB in the Intense R kit. Sections were counterstained
with Heamatoxylin and mounted using DPX (CellPath, SEA-1300-00A).
IHC slides were scanned using a Leica SCN 400F scanner at ×20 magnification
and images uploaded to Halo Image analysis platform (Indica Labs.). Images were
analysed using the CytoNuclear v1.5 algorithm. The percentage of Ki67 or Cleaved
Caspase 3 positive cells in prostate tumours or lymph nodes was calculated.
Additional measurements such as the average cell area and average cytoplasmic
area were also taken.
Fig. 8 IQSEC1 is associated with metastasis, treatment resistance, and poor clinical outcome. a and b CN increase in IQSEC1, ARF5, ARF6 across
indicated cohorts. AD, prostate adenocarcinoma; NE neuroendocrine; CR Castrate-resistant. c–j Clinical metrics (% samples) between IQSEC1 CN-amplified
(+) or non-amplified group (−) for c 3p Status (−, n= 420; +, n= 32), d Gleason Score (−, n= 779; +, n= 53), e Tumour Lymph Node Status. N0, no
positivity. N1, positivity. (−, n= 381; +, n= 36), f Sample Type (−, n= 1,797; +, n= 272), g Tumour Anatomic Site (−, n= 525; +, n= 78), h androgen
deprivation therapy. Luteinizing hormone-releasing hormone, LHRH (−, n= 484; +, n= 30), i person neoplasm status (−, n= 299; +, n= 77), and
j androgen receptor (AR) isoform v7 mRNA levels (Log2) (−, n= 221; +, n= 69). p values, c–i Chi-squared Test or j Kruskal–Wallis Test; Q values,
Benjamini–Hochberg adjustment. Box-and-whiskers plots: 10–90 percentile; +, mean; dots, outliers; midline, median; boundaries, quartiles. k Prostate-
specific antigen (PSA) serum levels (Log2) in IQSEC1, ARF5, ARF6 CN increase (+, n= 22) or not (−, n= 86) patients. Q value, Kruskal–Wallis Test. Box-
and-whiskers plots: 10–90 percentile; +, mean; dots, outliers; midline, median; boundaries, quartiles. l–n Copy Number Alteration (l, m) or (n) mutation
frequencies between IQSEC1 CN-amplified (n= 849) or unaltered (n= 2308) patients. Group association: Red, IQSEC1 CN increase; blue, unaltered. Q-
values, one-sided Fisher exact test with Benjamini–Hochberg adjustment. o and p Overall survival (% patients, months), unaltered compared to (i) IQSEC1
CN increase or (ii) combined IQSEC1, ARF5, ARF6 CN increase for o cohorts in A (n= 665) or p pan-cancer TCGA cohorts (n= 9307). p-values, Log-rank
t-test. q and r Matched Normal (blue) and prostate tumour (Tumour, red) Log2-normalised IQSEC1 mRNA for q total isoforms or r v2-v1 ratio. values. Line:
unbroken, tumour-increased; dotted, tumour-decreased. n= 52. p-values, Independent Groups t-test. s IQSEC1 mRNA log2-normalised normal–tumour
ratio across pan-cancer TCGA cohorts for total (green-magenta), individual isoforms (blue-red), or v2-v1 ratio (grey-orange). Circle size, p-value,
Independent Groups t-test. Normal tissue (n= 643), tumour tissue (n= 6716). Supplementary Table 2 contains tumour-type data. t PI3K-AKT pathway
(RPPA of pan-cancer TCGA cohorts) from median-split of Log2-transformed IQSEC1 mRNA. Red, high IQSEC1 co-occurring; blue, low IQSEC1 co-occurring.
Only cancer types presenting increased AKT_pS473 included. Row sorting from dendrogram. Circle size, p-value, Independent Groups t-test.
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Met uptake assay. Met uptake assays were performed using a fluorescently
labelled Met-647 antibody (BD Biosciences) to assess the cells’ ability to internalise
and traffic Met. Cells plated on 5 × 96-well plates were equilibrated at 37 °C for 1 h
in antibody binding medium (RPMI+ 0.5% BSA+ 1M CaCl2, pH 7.4). Cells were
washed twice with ice-cold PBS, incubated with Met-647-conjugated antibody for
1 h at 4 °C (1:100) then washed again with PBS. One plate was fixed as described
above. Two plates were treated with HGF (50 ng/μl) and chloroquine (100 μM)
diluted in pre-warmed medium for 10 or 30 min at 37 °C. They were then acid
stripped (washed three times at 4 °C with 0.5 M acetic acid, 0.5 M NaCl in PBS) and
fixed as previously described. The remaining two plates were incubated at 17 °C
with pre-warmed medium supplemented with HGF and chloroquine for 1 h. Acid
stripping was performed and plates maintained at 37 °C without HGF or chlor-
oquine for 10 min or 30 min prior to fixation. Cells were stained with Hoechst and
phalloidin and imaged using the Opera Phenix™ High Content analysis system.
Data are presented as line graphs that show normalised (Z-score) relative region
intensities compared to the intensity of the whole cell. Box and whiskers plot shows
total normalised (Z-score) intensity throughout the cells. N= 2 independent
experiments, 4 replicates/condition with the following total number of cells
examined per experiment: For internalisation at 0 min (Scramble 421, shIQSEC1
546), 10 min (Scramble 122, shIQSEC1 126), or 30 min (Scramble 93, shIQSEC1
120), and for recycling at 10 min (Scramble 150, shIQSEC1 136) or 30 min
(Scramble 219, shIQSEC1 282) cells examined per experiment. p values were cal-
culated using Welch’s 2-tailed t-test and are shown on each graph as follows; n.s.=
not significant, **p ≤ 0.01, ***p ≤ 0.001 and ****p < 0.0001.
Protein purification. pET20b-6xHis-ARF5D17 or pGEX-5x-1-hGGA3 [VHS-
GAT] were transformed into BL21 (DE3) pLysS bacteria (Promega). Single colo-
nies were grown in lysogeny broth (LB) medium in appropriate antibiotics until
OD600nm of 0.3. Protein expression was induced using 200 μM isopropyl β-D-1-
thiogalactopyranoside (IPTG, Sigma). Bacterial cells were pelleted and resuspended
in 20 ml Buffer A (for His-tagged: 20 mM Tris, 300 mM NaCl, 5 mM MgCl2, 150 μl
BME; for GST-tagged: 20 mM Tris, 150 mM NaCl, 5 mM MgCl2, 150 μl BME)
containing protease inhibitors. DNAse (Sigma) was added to the lysate. Bacteria
were lysed by passing through a 20,000 psi-pressurised microfluidizer. Lysates were
collected at 20,000×g for 40 min at 4 °C and soluble proteins in the supernatant
were sterile filtered 5 μm PVDF Membrane (Merck).
PCR products encoding human IQSEC1-SEC7-PH (residues 517-866 based on
variant 2 numbering) WT and GEF-dead (E620K) were cloned into pEGFP-C1
fused with an N-terminal 12xHis tag followed by a 6× Glycine linker replacing the
GFP sequence. HEK293 suspension cells were transfected with constructs using
polyethylenimine (PEI, Sigma). HEK293 suspension cells were cultured at 37 °C
and 8% CO2 and 2×g. Cells were collected after 4 days, resuspended in
His–IQSEC1 Buffer A (40 mM Tris 7.5 pH, 300 mM NaCl, 5 mM MgCl2, 60 μl
β-mercaptoethanol, 25 mM Imidozol) and sonicated. Soluble fraction was collected
at 40 min, 21,000×g at 4 °C and sterile-filtered using a 0.45 μm PVDF-membrane
(Merck).
Soluble fractions were loaded onto an ÄKTA purification system (GE
Healthcare) using an equilibrated HisTrap or GSTrap (both GE Healthcare)
column. The protein containing fraction was loaded onto the column at 1 ml/min.
Proteins were eluted from columns using an imidozol gradient buffer (25–300 mM)
or glutathione elution buffer (150 mM NaCl, 25 mM Tris, 20 mM glutathione) for
His-tagged or GST-tagged proteins, respectively. Protein containing fractions were
concentrated (Amigon Ultra-15 centrifuge filter) and gel purified on an appropriate
size exclusion column (Superose-6 10–300 GL 24 ml for His-tagged IQSEC1,
S75 16–600 120 ml for His-tagged ARF5, S200 16–600 120 ml for GST-GGA3)
in gel filtration (GF) buffer (20 mM Tris, 150 mM NaCl, 1 mM DTT, 5 mM
MgCl2). Fractions containing purified proteins were concentrated, snap frozen
and stored at −80 °C.
Fluorescent polarisation assay. Nucleotide exchange of ARF5 protein was
examined by observing changes in fluorescent polarisation. 100 μM recombinant
ARF protein was incubated with 200 μM mantGDP and 50mM EDTA in gel
filtration buffer (GF) (20 mM Tris, 150 mM NaCl, 1 mm DTT) overnight at 18 °C.
100 mM MgCl2 was added to stop the exchange reaction. A PD10 (GE Healthcare)
desalting column was then washed with GF buffer containing 5 mM MgCl2, 500 μl
of sample added and then eluted with GF buffer. Protein concentration was
determined using a Bradford assay as per manufacturers instructions. 20 μM of
GDP nucleotide and 2 μM of GEF protein was sequentially added to 1 μM ARF and
polarisation changes measured with a Photon Multiplier Detection System (Photon
International Technology). Excitation was set to 366 nm and emission to 450 nm.
Inhibitors were added to the reaction prior to addition of GEF protein.
Proliferation assays. PC3 cells were plated in a 96-well ImageLock plate, in tri-
plicate for 24 h. Imaging was carried out on IncuCyte® ZOOM each hour for 48 h.
Cell area per well was then measured using the IncuCyte® ZOOM analysis software.
n= 3 independent experiments with three replicates per condition. p-values
(Student’s t-test): **p ≤ 0.01 and ****p ≤ 0.0001.
Invasion and migration assays. ImageLock plates were coated with 10% GFRM
diluted in medium overnight at 37 °C. Cells were re-suspended in 100 μl medium
and plated for 4 h at 37 °C. The resultant monolayer was wounded using a wound
making tool (Essen Biosciences), washed twice with medium to remove debris, and
overlaid with either 50 μl of 25% GFRM for invasion assays or 100 μl medium for
migration assays. After an hour at 37 °C 100 μl medium was added to invasion
assays and plates imaged every hour for 4 days using the IncuCyte® ZOOM.
The number of independent experiments (n) and technical replicates per experi-
ment is stated in the appropriate figure legend. Results are presented as relative
wound density (RWD) for each time point and for the time point at which the
average RWD of the control samples is 50% (Tmax1/2). Values are mean ± s.d.,
p values were calculated using a Student’s 2-tailed t-test and are shown on each
graph as follows; n.s.= not significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and
****p < 0.0001.
Immunoblotting. Cells were plated for 24 h prior to treatment with growth factors
or inhibitors for a further 24 h. Plates were washed twice with ice cold PBS then
lysis buffer added for 15 min (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.5 mM
MgCl2, 0.2 mM EGTA, and 1% Triton X-100 with cOmplete protease inhibitor
cocktail and PhosSTOP tablets (Roche). Cells were scraped and lysates clarified by
centrifugation at 216×g at 4 °C for 15 min. BCA Protein Assay kit (Pierce) was used
to determine protein concentration. SDS–PAGE was then performed and proteins
transferred to PVDF membranes using the iBlot 2 transfer system (Thermo Fisher
Scientific). Membranes were incubated for an hour in Rockland blocking buffer
(Rockland) and primary antibodies added overnight at 4 °C (1:1000 unless stated
otherwise). Antibodies used were as follows: anti-GAPDH (CST 2118 1:5000), anti-
IQSEC1 (Sigma G4798), anti-IQSEC1 (Caltag-Medsystems PSI-8009), anti-GFP
(Merck 000000011814460001), anti-LRP1 (Sigma L2295), anti-Met (CST 3127),
anti-Met phospho 1234/1235 (CST 3077), anti-Akt (CST 2920), anti-Akt phospho
S473 (CST 3787), anti-ARF1 (Novus Biologicals NB-110-85530), anti-ARF6 (Sigma
A5230), ARF5 (Novus Biologicals H00000381-M01), anti-ARFGAP1 (Sigma
HPA051019), anti-SORL1 (BD 611860), anti-Sin1 (CST 12860), anti-RICTOR
(CST 2114), anti-PPC6 (Sigma HPA050940 1:250), anti-14-3-3ζ/Δ (CST 7413),
anti-PIP5Ka (CST 9693) and PIP5Kb (Sigma K0767). After addition of appropriate
secondary antibodies for 45 min, membranes were washed three times in TBST and
imaged using a ChemiDoc Imager (BioRad) or Odyssey Imaging System (LI-COR
Biosciences). Bands were quantified using Image Lab 6.1 (BioRad) or Image Studio
Software 6.0 (LI-COR Biosciences). The number of independent experiments (n) is
stated in the appropriate figure legend and quantitation is shown as mean ± s.d., p
values were calculated using a Student 2-tailed t-test, unless otherwise stated, and
are shown on each graph as follows; n.s.= not significant, *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001 and ****p < 0.0001. GAPDH was used as a loading control for each
immunoblot and a representative image for each sample set is shown where
appropriate.
GFP Trap and Immunoprecipitation. Immune complexes were collected when
1 mg of cell lysate was immunoprecipitated with anti-Met antibody (CST 3127,
1:50) overnight at 4 oC with rotation. Anti-mouse agarose or mouse agarose (both
Sigma) were added for 1 h at 4 °C prior to three washes in lysis buffer. Samples
were then separated by SDS–PAGE, transferred to a PVDF membrane and
immunoblotted. Lysates from cells expressing GFP-tagged proteins were immu-
noprecipitated using a GFP-Trap Kit (Chromotek) as per manufacturer’s
instructions and immunoblotting performed as above. n= 3 and quantitation is
shown as mean ± s.d.
Mass spectrometry. For mass spectrometry analysis agarose beads were resus-
pended in a 2 M urea and 100 mM ammonium bicarbonate buffer and stored at
−20 °C. On-bead digestion was performed from the supernatants. Triplicate bio-
logical replicates were digested with 25 µl 2M urea in 50 mM Tris, pH 7.5, 1 mM
DTT, and 150 ng EndoLysC (Alpha Laboratories) and 150 ng trypsin (Promega) on
beads Lys-C (Alpha Laboratories) and trypsin (Promega) on beads as according to
optimised approaches76. Tryptic peptides were separated on a 20 cm fused silica
emitter (New Objective) packed in house with reverse phase Reprosil Pur Basic
1.9 μm (Dr. Maisch GmbH) using an EASY-nLC 1200 (Thermo Fisher Scientific)
coupled online to an Orbitrap Q-Exactive HF mass spectrometer (Thermo Fisher
Scientific) via nanoelectrospray ion source (Thermo Fisher Scientific). For the full
scan a resolution of 60,000 at 250Th was used. The top ten most intense ions in the
full MS were isolated for fragmentation with a target of 50,000 ions at a resolution
of 15,000 at 250Th. MS data acquisition were performed using the XCalibur
software (Thermo Fisher Scientific). The MaxQuant software version 1.5.5.177 was
used to process MS Raw files and searched with Andromeda search engine78,
querying UniProt79. Database was searched requiring specificity for trypsin clea-
vage and allowing maximum two missed cleavages. Methionine oxidation and N-
terminal acetylation were specified as variable modifications, and Cysteine carba-
midomethylation as fixed modification. The peptide and protein false discovery
rate (FDR) was set to 1%. The common reverse and contaminant hits (as defined in
MaxQuant output) were removed. Only protein groups identified with at least one
uniquely assigned peptide were used for quantification. For label-free quantitation,
proteins quantified in all three replicates in at least one group, were measured
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according to the label-free quantitation algorithm available in MaxQuant80. Sig-
nificantly enriched proteins were selected using a Welch t-test with a 5% FDR
(permutation based). Hits were prioritised based on fold change expression data
mined from publicly available RNAseq data from PC3 sublines from published
data sets (PC3E versus GS689.Li; SRS354082 [https://www.ncbi.nlm.nih.gov/
sra/?term=SRS354082]) and PC3-Epi versus PC3-EMT14; GSE48230 [https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48230]39,40.
GGA3 pulldown. A pulldown assay was performed to examine GTP-loading of
ARF proteins using the ARF-GTP-specific binding domain of GGA3. Cells were
cultured for 48 h then serum starved overnight. HGF in serum free medium was
added for 30 min. Cells were then lysed on ice in pulldown-lysis buffer (50 mM
Tris, 100 mM NaCl, 2 mM MgCl2, 0.1% SDS, 0.5% Na-deoxycholate, 1% Triton X-
100, 10% glycerol), syringed five times and centrifuged at 4 °C 14,000×g for 1 min.
Spin columns were equilibrated with 50 μl of glutathione agarose resin and washed
with pulldown-column wash buffer (1:1 pulldown-lysis buffer and 1×TBS). 80 μg of
GST-GGA3-GAT recombinant fusion protein was immobilised on the agarose
resin by incubation at 4 °C with gentle rocking for 1 h. 1.5 mg of lysate was added
onto spin columns and incubated at 4 °C for 2 h with rocking. Unbound proteins
were washed off the column with pulldown-wash buffer (50 mM Tris, 100 mM
NaCl, 2 mM MgCl2, 1% NP-40, 10% glycerol). 60 μl of pulldown-elution buffer
(10 mM glutathione in 1×TBS) was added to the spin column and incubated for
5 min at RT. Eluted protein was collected at 1250×g for 1 min and samples were
prepared for SDS–PAGE and western blotting as described above.
qPCR. RNA was extracted using an RNeasy kit (Qiagen) and reverse transcription
of RNA performed using a High-Capacity cDNA Reverse Transcription Kit
(Thermo Fisher Scientific) following the manufacturer’s protocols. TaqMan qPCR
was then carried out as per manufacturer’s instructions (Thermo Fisher Scientific).
n= 3 technical replicates. Data were analysed using the Applied Biosystems 7500
Software v2.0.6 and the relative quantitation (RQ) was calculated using the com-
parative Ct (ΔΔCt) method. ARF and ARFGEF expressions were detected using a
custom qPCR primer panel. Details are available on request.
Analysis of patient cohorts. The majority of patient data (Copy number, muta-
tional status, RNAseq, RPPA, co-expression matrices and clinical annotation) was
accessed, analysed and downloaded using in-platform cBioportal.org tools81,82.
Normal versus Tumour RNAseq, including transcript variant expression, was
obtained by downloading IQSEC1 variant annotation across the TCGA pan cancer
dataset using the TCGA Splicing Variants Database (www.TSVdb.com)83. RPPA
and IQSEC1 variant data were analysed using custom KNIME Data Analytics
Platform (Version 3.3.1) pipelines.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this paper.
Data availability
The proteomic data generated in this work have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository84 with the dataset identifier PXD013810.
The RNAseq data from PC3 sublines in this study are available in either the Short Read
Archive database for PC3E, GS689.Li in SRS354082), or the Gene Expression Omnibus
for PC3-Epi, PC3-EMT14 in GSE48230. Any other data that supports the findings of this
study are available from the corresponding author upon reasonable request. Source data
are provided with this paper.
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